$UCB

UNITED COMMUNITY BANKS INC

Insider trades
2
2
0
$74K
$935K
BRADSHAW RICHARD
50%
See all $UCB insider activity →

UNITED COMMUNITY BANKS INC (UCB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

UNITED COMMUNITY BANKS INC (UCB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ucbi-20260819 0000857855 false 0000857855 2026-08-19 2026-08-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

UCB, BB join hands boosting rural finance

Bangladesh Bank (BB) and United Commercial Bank (UCB) agreed to expand rural financing. UCB will provide loans under BB's TK 10,000 crore refinance scheme, supporting agriculture and rural businesses. Loans will have a max 8% interest rate and 18-month tenure, aiming to boost food security and employment.

UCB sentiment & insider activity

Over the past 7 days, alphai's AI scored 4 news stories mentioning UCB (UNITED COMMUNITY BANKS INC). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.

Recent UCB coverage spans corporate actions, financial news and macro economy.

In the last 30 days, UCB insiders filed 4 SEC Form 4 transactions — 1 purchase ($74K) and 3 sales ($935K). The most active reporter was BRADSHAW RICHARD, EVP, Chief Banking Officer, with 2 filings. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving UCB

alphai scores every news story that mentions UCB with an AI model for sentiment and relevance, and aggregates insider trades from UNITED COMMUNITY BANKS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $UCB

Score
$UCBMed

UNITED COMMUNITY BANKS INC (UCB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

UNITED COMMUNITY BANKS INC (UCB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ucbi-20260819 0000857855 false 0000857855 2026-08-19 2026-08-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

UCB, BB join hands boosting rural finance

Bangladesh Bank (BB) and United Commercial Bank (UCB) agreed to expand rural financing. UCB will provide loans under BB's TK 10,000 crore refinance scheme, supporting agriculture and rural businesses. Loans will have a max 8% interest rate and 18-month tenure, aiming to boost food security and employment.

$UCBMed

UCB to exit National Housing by offloading entire stake

UCB plans to sell its remaining 5.63 lakh shares in National Housing Finance via the Dhaka Stock Exchange within 30 days. National Housing's shares rose 0.68% to Tk29.40. The company reported improved EPS and NOCFPS for H1 2026, with a recommended 10% dividend for 2025.

$UCBMed

UCB’s pipeline strategy in 2026: Doubling down on immunology and neurology

UCB outlined a 2026 pipeline strategy focused on immunology and neurology, using dealmaking and newer modalities rather than new therapeutic areas. In the past year it acquired Neurona Therapeutics and Candid Therapeutics and licensed ATG-201 from Antengene. Bimzelx sales rose from €607m in 2024 to €2.22b in 2025. UCB is advancing dapirolizumab pegol with Biogen and rozanolixizumab in neurology.

Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome

UCB said EpilepsiaOpen published post hoc results from an open-label extension of FINTEPLA (fenfluramine) in Lennox-Gastaut syndrome. In 247 patients continuing from a Phase 3 trial, median seizure reductions ranged from -32.1% at Month 1 to about -48% by Months 4-6, with CGI-I global improvements by Month 12. Safety matched known effects, with TEAEs highest at initiation and declining over time. UCB reported 2025 revenue of €7.7 billion.

Related tickers